Agile Therapeutics Reports Third Quarter 2018 Financial Results
Agile Therapeutics, Inc. (AGRX)
Last agile therapeutics, inc. earnings: 5/2 04:15 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.agiletherapeutics.com/investor-relations
Company Research
Source: GlobeNewswire
Cash Expected to Enable Company to Fund Operations into Second Quarter 2019 PRINCETON, N.J., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial results for the three and nine months ended September 30, 2018 and provided a corporate update. Third quarter 2018 and other recent corporate developments: Twirla® Update – As previously announced, Agile initiated formal dispute resolution with the U.S. Food and Drug Administration’s (FDA) Office of Drug Evaluation III (ODE III) on June 6, 2018 to appeal the complete response letter (CRL) the FDA issued in December 2017 relating to the New Drug Application (NDA) for Twirla (AG200-15), the Company’s investigational non-daily, low-dose combination hormonal contraceptive patch. In October 2018, the FDA’s Office of New Drugs (OND) formally denied the Company’s appeal and provided a path forward for resubmission of the NDA for Tw
Show less
Read more
Impact Snapshot
Event Time:
AGRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGRX alerts
High impacting Agile Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AGRX
News
- Agile Therapeutics Announces Delisting from Nasdaq [Yahoo! Finance]Yahoo! Finance
- Agile Therapeutics Announces Delisting from NasdaqGlobeNewswire
- Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024GlobeNewswire
- Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024GlobeNewswire
- Agile Therapeutics, Inc. (NASDAQ: AGRX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
AGRX
Earnings
- 11/9/23 - Beat
AGRX
Sec Filings
- 3/28/24 - Form 8-K
- 3/25/24 - Form 8-K
- 3/14/24 - Form 8-K
- AGRX's page on the SEC website